Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Phase 2 Completed 140 enrolled Aptabio Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.

Timeline

Start: 2020-08-24
Primary completion: 2021-07-26
Completion: 2021-08-23

Publications

Jang J, Yu H, Oh EB, Park JW, Kim S, Kim T, Sohn J, Jin BR, Chang TS. Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. Antioxid Redox Signal. 2025 Aug;43(4-6):288-307. doi: 10.1089/ars.2024.0695. Epub 2025 Apr 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isuzinaxib	Small molecule	400 mg	Oral

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Summary

Timeline

Publications

Drugs

Indications